Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Amgen advances clinical research with promising data in cardiovascular disease and cancer, reinforcing its commitment to innovation and …
Major pharma players unveil significant clinical trial progress and strategic collaborations targeting obesity and cardiovascular health.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Partnerships harnessing artificial intelligence are revolutionizing drug discovery, reducing timelines and improving candidate success rates.
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Already a subscriber? Log in